Reboxetine, a selective norepinephrine reuptake inhibitor normally prescribed for depression, can reduce sleep apnea symptom severity.
Sufferers of obstructive sleep apnea are at increased risk of developing cancer and thrombosis. In those over 74, OSA was associated with an increased risk of cognitive decline.
People who snore and those with obstructive sleep apnea tend to be less active during the day.
Obstructive sleep apnea may impact your behavior when driving, a new study reports. People with sleep apnea who experienced eight additional disruptions in breathing per hour had a 27% increased risk of making dangerous driving moves, such as speeding, hard breaking , or accelerating suddenly.
Sulthiame, a CA inhibitor drug, reduced the number of breathing pauses and promoted oxygenation during the night in sufferers of obstructive sleep apnea.
Untreated obstructive sleep apnea can accelerate biological aging, but treating OSA can slow or even reverse the process.
Two existing medications have been repurposed to treat sleep apnea. Researchers report the medications reduce symptoms of sleep apnea by 30%.
People with sleep apnea who were exposed to positive airway pressure therapy had a reduced risk of being diagnosed with dementia.
Obstructive sleep apnea is common in people with cognitive impairment, researchers report. The severity of obstructive sleep apnea correlated with the degree of cognitive impairment.
Poor sleep and inadequate oxygen supply associated with obstructive sleep apnea appears to affect cytokines. This could explain the link between OSA and an increased risk of autoimmune disorders, such as rheumatoid arthritis.
Severe obstructive sleep apnea is linked to an increase of the amyloid beta protein, resulting in a greater risk of sufferers developing dementia.
Amyloid plaques form in the same location and spread in the same way in the brains of people with both obstructive sleep apnea and Alzheimer's disease.
